Canaccord Genuity Group reissued their buy rating on shares of Diaceutics (LON:DXRX - Free Report) in a report released on Tuesday morning, Marketbeat Ratings reports. Canaccord Genuity Group currently has a GBX 160 ($2.01) target price on the stock.
Separately, Canaccord Genuity Group reiterated a "buy" rating and set a GBX 160 ($2.01) price objective on shares of Diaceutics in a research report on Tuesday.
View Our Latest Stock Analysis on DXRX
Diaceutics Price Performance
DXRX traded down GBX 3.50 ($0.04) during trading on Tuesday, reaching GBX 120.50 ($1.51). The stock had a trading volume of 35,123 shares, compared to its average volume of 108,035. The business has a 50-day moving average of GBX 121.99 and a 200-day moving average of GBX 126.21. Diaceutics has a one year low of GBX 84.50 ($1.06) and a one year high of GBX 136 ($1.71). The company has a debt-to-equity ratio of 2.93, a quick ratio of 9.92 and a current ratio of 4.85. The stock has a market cap of £101.79 million, a PE ratio of -4,016.67 and a beta of 0.58.
Diaceutics Company Profile
(
Get Free Report)
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.
See Also
Before you consider Diaceutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diaceutics wasn't on the list.
While Diaceutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
